**Supplementary Figure 1** Dose escalation flow chart. DLT – dose limiting toxicity, MTD – maximum tolerated dose

**Supplementary Figure 2** qPCR of CEBPA mRNA levels at days 2, 8 and 15 following treatment

**Supplementary Figure 3** Longitudinal changes in WBC mRNA expression of CEBPA, adenosine, PD-1 & CXCR4 at screening, day2, 8 and 15 of a single patient treated in the 130mg/m2 cohort

**Supplementary Figure 4** A) CT and MRI of patient with prolonged partial response with MTL-CEBPA treatment B) IFN-gamma, NFkB and IL6 trend at days 1, 8 and 15 following treatment and C) AFP change at from baseline to 4, 8 and 16 weeks on treatment

**Supplementary Figure 5** showing complete radiological response of lung metastases